Demcizumab (Anti-DLL4)

Demcizumab (Anti-DLL4) is a monoclonal antibody taregting DLL4. Demcizumab is a potent inhibitor of the Notch pathway. Demcizumab alone or in combination with chemotherapy is effective in various cancer models. MW: 145.5 KD.

Price Not Available 1mg*5 Demcizumab (Anti-DLL4) Supplier Page
Trivial name OMP 21M18; Human Anti-TNFRSF10B Recombinant Antibody
Catalog Number A2520
CAS# 1243262-17-0
Size 1mg*5
Supplier Page http://www.selleckchem.com/products/demcizumab-anti-dll4.html